ScinoPharm Opens $113 Million API Plant In Mainland China
This article was originally published in PharmAsia News
Executive Summary
ScinoPharm held a grand opening of its new plant in mainland China, a $113 million facility intended to produce active pharmaceutical ingredients for sale in China.